NervGen Pharma (TSE:NGEN) has released an update.
Stay Ahead of the Market:
- Discover outperforming stocks and invest smarter with Top Smart Score Stocks
- Filter, analyze, and streamline your search for investment opportunities using Tipranks' Stock Screener
NervGen Pharma, a clinical-stage biotech firm focusing on nervous system repair, has announced that its Chief Medical Officer will present at the U2FP 19th Annual Science & Advocacy Symposium. The presentation will discuss the challenges of translating spinal cord injury treatments from animal models to human clinical trials. NervGen holds exclusive rights to NVG-291, a peptide showing promise in nervous system repair, and is conducting a Phase 1b/2a trial to assess its efficacy in spinal cord injury recovery.
For further insights into TSE:NGEN stock, check out TipRanks’ Stock Analysis page.
